Detalhe da pesquisa
1.
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Blood
; 135(7): 463-471, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31841594
2.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29860938
3.
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Lancet Haematol
; 10(1): e46-e58, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36370742
4.
A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.
Leuk Lymphoma
; 62(13): 3192-3203, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34323164
5.
Examining racial differences in diffuse large B-cell lymphoma presentation and survival.
Leuk Lymphoma
; 54(2): 268-76, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22800091